1. P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS. (23rd June 2022) Authors: Jeyaraju, D.; Alapa, M.; Polonskaia, A.; Risueno Perez, A.; Hurren, R.; Wang, X.; Gronda, M.; Ahsan, A.; Wang, C.; Subramanyam, P.; Sriganesh, J.; Anand, A.; Bysani Reddy, M.; Ghosh, K.; Kyriakopoulos, C.; Lailler, N.; Hartl, C.; Lopes de Menezes, D.; Schimmer, A.; Hagner, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS). (23rd June 2022) Authors: Wei, A. H.; Carraway, H. E.; Taningco, L.; Laille, E.; Gong, J.; Prebet, T.; Lopes de Menezes, D.; Ravandi, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗